HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.2350
-0.0050 (-2.08%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.2400
Open0.2350
Bid0.2300 x 0
Ask0.2400 x 0
Day's Range0.2300 - 0.2400
52 Week Range0.0750 - 0.9400
Volume1,709,504
Avg. Volume5,876,547
Market Cap326.685M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile10 days ago

    FSD Pharma CEO Lays Out Roadmap in Exclusive Interview with CFN Media

    Seattle, Washigton--(Newsfile Corp. - May 10, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSSDF). The company is a licensed producer focused on building out a 3.9 million sq. ft. indoor hydroponic facility near Toronto capable of producing 400,000 kilograms of dried cannabis per year. With a newly ...

  • Newsfile12 days ago

    FSD Pharma Investments Pay Off Amid Robust Expansion at Ontario Facility -- CFN Media

    Seattle, Washington--(Newsfile Corp. - May 8, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSSDF). The company reported its fourth quarter financial results following a major year of accomplishments. Based in Cobourg, Ontario, the company's massive former Kraft Foods facility sits on 72 acres of land with nearly four ...

  • FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids
    CNW Group13 days ago

    FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids

    TORONTO , May 7, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (FSDDF) (FRA: 0K9) ("FSD Pharma" or "FSD") and Solarvest BioEnergy Inc. (SVS.V) ("Solarvest"), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement. Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma and Solarvest have made investments into one another and FSD has the option to enter into an exclusive license arrangement over a subset of the project and receive royalty rights over all of the products that result from the project.

  • FSD Pharma Reports 2018 Year-End Results
    CNW Group14 days ago

    FSD Pharma Reports 2018 Year-End Results

    TORONTO , May 6, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (FSDDF) (FRA: 0K9) ("FSD Pharma", "FSD" or "the Company") today reported its financial and operational results for the fourth quarter and fiscal year-ended December 31, 2018 . "FSD has fully complied with all Required Filings with Canadian securities regulators.

  • FSD Pharma provides update on status of 2018 year-end filings
    CNW Group17 days ago

    FSD Pharma provides update on status of 2018 year-end filings

    FSD Pharma provides update on status of 2018 year-end filings

  • Business Wire17 days ago

    FSD Pharma Provides Update on Status of 2018 Year-End Filings

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD Pharma” or “FSD”) announces this morning that it has been delayed in filing its audited annual financial statements for the period ending December 31, 2018, the related management’s discussion and analysis and the certificates of its CEO and CFO (collectively the “Required Filings”) with Canadian securities regulators. “2018 was an extraordinary year for FSD” said recently appointed CEO Dr Raza Bohkari.

  • Newsfile19 days ago

    FSD Pharma Doubles Down on Endocannabinoid-based Pain Management -- CFN Media

    Seattle, Washington--(Newsfile Corp. - May 1, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FSE: 0K9). The company has already staked out its plans to address this crisis through endocannabinoid-based treatment options. After partnering with SciCann Therapeutics, the company recently announced the planned acquisition of a specialty ...

  • Market Exclusive20 days ago

    FSD Pharma Gets Approval to Get Cannabis Products

    FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) said that its FV Pharma subsidiary received its Sale For Medical Purposes license for the sale of cannabis products. The license, which went into effect on April 18, allows the current FSD facility to supply and sell cannabis products under the Cannabis Act Canada. The company anticipates […]The post FSD Pharma Gets Approval to Get Cannabis Products appeared first on Market Exclusive.

  • FSD Pharma and MP Kim Rudd Host Media Event at Cobourg Production Facility
    CNW Group23 days ago

    FSD Pharma and MP Kim Rudd Host Media Event at Cobourg Production Facility

    TORONTO , April 26, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) announced today that in celebration of its wholly-owned subsidiary FV Pharma Inc. having been awarded a sales license by Health Canada, the company is hosting a media event at its headquarters in Cobourg at 520 William St., a former Kraft plant. Presenting at the event are the Company's senior management team members, local MP, Kim Rudd and Cobourg Mayor, John Henderson . "The sales license is the last step in our official entrance to the national cannabis market.

  • FSD Pharma Announces Share Exchange Transaction with Aura Health
    CNW Group26 days ago

    FSD Pharma Announces Share Exchange Transaction with Aura Health

    TORONTO , April 24, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) announced today that it has entered into a share exchange transaction with Aura Health Inc. ("Aura"). Pursuant to the agreement, FSD acquired 13,562,386 Aura shares valued at $3 million issued from treasury in exchange for 13,181,019 FSD shares issued from treasury valued at $3 million . Aura Health is a Toronto -based cannabis company building an international network of vertically integrated businesses in the medical cannabis industry.

  • Newsfile27 days ago

    InvestmentPitch Media Video Discusses FSD Pharma and its New Additional License to Sell Cannabis for Medical Purposes - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF) announced that its wholly-owned subsidiary FV Pharma, currently a licensed cannabis producer, has received its "Sale for Medical Purposes" license under the Cannabis Act in Canada. This additional license permits the current FSD facility to supply and sell cannabis products, with management anticipating an amended sales license in the near future to include the sale ...

  • Newsfile27 days ago

    FSD Pharma Secures Sales License for Massive Production Facility -- CFN Media

    Seattle, Washington--(Newsfile Corp. - April 23, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9). The company became the latest licensed producer to possess both cultivation and sales licenses on April 22 after securing its cannabis sales license from Health Canada. With nearly four million sq. ...

  • FSD Pharma to Acquire Prismic Pharmaceuticals
    CNW Group27 days ago

    FSD Pharma to Acquire Prismic Pharmaceuticals

    TORONTO , April 23, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD Pharma" or the "Company") and Prismic Pharmaceuticals Inc. ("Prismic"), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the "Agreement") pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic (the "Transaction"). Prismic is developing novel non-addictive prescription drugs with unique safety profiles with the goal of addressing the opioid crisis based on formulations utilizing micro-palmitoylethanolamide's ("PEA") "entourage" effect on certain drugs impacting the endocannabinoid system.

  • Newsfile28 days ago

    FSD Pharma Receives Cannabis Sales License from Health Canada

    \- New license positions FSD to serve the growing medicinal use markets - Toronto, Ontario--(Newsfile Corp. - April 22, 2019) - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019.The license allows the current FSD facility ...

  • FSD Pharma to Present at Arcview Investor Forum
    CNW Grouplast month

    FSD Pharma to Present at Arcview Investor Forum

    TORONTO , April 17, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), announced today that Dr. Raza Bokhari , Co-Chairman and Chief Executive Officer of FSD Pharma will participate in the Arcview Investor Forum being held April 23-25, 2019 , in Vancouver . Dr. Sara May , the recently appointed president of FV Pharma, will participate in a panel about investing in plant genetics. FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome.

  • Newsfilelast month

    FSD Pharma, Experienced CEO Has Brought Good Returns for Investors, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - April 12, 2019) - New CEO Raza Bokhari discusses exciting partnerships with Canntab and World Class Extraction. If you cannot view the video above, please visit:https://www.b-tv.com/fsd-ceo-clip-90-sec-v3/FSD Pharma is being featured on BNN Bloomberg on Apr. 13 - Apr. 14, 2019, throughout the day and evenings.FSD Pharma (CSE: HUGE)fsdpharma.comAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 ...

  • GlobeNewswirelast month

    FSD Pharma Explores Insurance Coverage for Medical Cannabis in Canada -- CFN Media

    SEATTLE, April 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (HUGE.CN) (FSDDF) (FFT:0K9). The company has recognized these trends and recently hired an insurance expert to plan out its approach ahead of its sales license that’s expected later this year. Cannabis investors have been focused largely on the recreational market with the legalization of adult-use cannabis last year, but a growing body of research suggests that medical cannabis remains a compelling long-term opportunity.